Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 20/20 | 0.64 |
| ▸ | MMP1 | P03956 | 19/20 | 0.64 |
| ▸ | MMP9 | P14780 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505109 | 0.88 | MMP13 (0.60) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6500027 | 0.88 | MMP13 (0.76) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6499477 | 0.85 | MMP13 (0.58) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6504739 | 0.84 | MMP13 (0.70) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6506638 | 0.83 | MMP13 (0.59) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6507319 | 0.83 | ADAM17 (0.61) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6506270 | 0.81 | MMP13 (0.75) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6507364 | 0.81 | MMP13 (0.74) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6505770 | 0.78 | MMP13 (0.62) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL7442494 | 0.78 | MMP13 (0.69) | MMP13ADAM17MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | MMP13 114/4885ADAM17 29/4885MMP1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.